Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Primary Carcinomas of Choroid Plexus are seen rarely. In previous literature there were 37 cases which were reported according to Lewis and Russel-Rubinstein malignancy criterias. In this article, we describe 5 years old boy and 1.5 year old girl who suffered from cerebellar ataxia and intracranial pressure increase syndrome. In case 1, the tumor of the fourth ventricle was diagnosed by brachial angiography and ventriculography. In case 2, the diagnosis was established by CT scan. In case 1, the patient died during the postoperative course. In case 2, the postoperative time was unremarkable. A radiotherapy of 3 000 rads was applied to the posterior fossa. One year later, the patient had only mild ataxia.
 ...
PMID:[Primary carcinoma of the choroid plexus. 2 case reports and review of the literature]. 408 10

A 46-year-old man developed sudden dysarthria and atactic gait and was noted to be unable to get up even on the bed about one year prior to his death. By following several days, he started to have scanning speech, nausea, trancal ataxia and dysmetria in succession. The cerebro-spinal fluid yielded moderate pleocytosis. There were no sensory disturbance, pathological reflexes and Romberg's sign. Half a year later, submandibular tumor was noted. The biopsy showed metastatic small cell undifferentiated carcinoma, presumably of pulmonary origin, and paraneoplastic cerebellar degeneration was suspected. He died of bronchopneumonia, superimposed on lung cancer on February 25 in 1979. The necropsy showed a large tumor in the right lung which was histologically verified small cell undifferentiated carcinoma (so-called oat-cell carcinoma). The cerebellum disclosed diffuse cortical atrophy, chiefly of Purkinje cell type. Moderate demyelination with reparative gliosis and foamy macrophages was seen in the white matter, which was considered secondary to cortical devastation. The morphometric study on Purkinje cell loss showed interesting distribution of the lesions. The severely affected portions were the central lobe and culmen in the vermis, and the ala lobuli centralis and quadrangular lobe in the hemisphere, respectively. The lingula was strikingly spared. The finding was compared with that of other cerebellar disease in reviewing the literature.
 ...
PMID:[An autopsy case of carcinomatous subacute cerebellar degeneration--on distribution of cerebellar cortical lesions]. 609 6

A ferret with clinical and laboratory signs of hypoglycemia was found at surgery to have a beta cell tumor of the pancreas. There had been recurrent episodes of weakness, ataxia, dehydration, and hypothermia. A fasting blood glucose content was 43 mg/dl and the amended insulin/glucose ratio was 362.5. The tumor was removed, yet hypoglycemia persisted postoperatively. Clinical signs related to hypoglycemia did not recur following application of medical treatment and frequent feedings. The histologic appearance of the tumor closely resembles that which has been seen in other species.
 ...
PMID:Pancreatic beta cell tumor in a ferret. 609 38

Forty-five women with far-advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG), 1000 mg p.o. daily, and medroxyprogesterone acetate (MPA), 1500 mg p.o. daily. Of 41 patients evaluable for treatment response, there were two complete responses, five partial remissions, 26 patients with minor tumor responses or no change, and eight nonresponders. Major side effects included those known for AG and MPA, i.e., impairment of mental functions, depressive syndromes, fatigue, ataxia, skin rash, changes in body weight, and transient increase of gamma-glutamyl-transferase. Most side effects disappeared spontaneously after 4 to 6 weeks of treatment. Plasma hormone measurements in 28 patients revealed no impairment of adrenocorticotropic hormone and cortisol levels. In conclusion, in the AG combination, it is feasible and safe to replace cortisol by MPA. Treatment results warrant further investigation of AG-MPA in patients with breast cancer of a more favorable prognosis.
 ...
PMID:Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. 612 83

Four to twelve days following initial antibiotic treatment for a febrile illness, three adults suddenly experienced numbness and pain over the face and entire body. Each had received a penicillin or a semisynthetic derivative, and two patients also received other antibiotics. Signs appeared rapidly and included profound sensory ataxia, areflexia, and widespread sensory loss, primarily of large fiber modalities (proprioceptive sensibility). Slowed or absent sensory conduction was found. There was no weakness, and electrical study of muscle and motor nerve conduction was normal in all. The cerebrospinal fluid was acellular, and protein levels were elevated to 126 and 175 mg/dl in two cases and were normal in the other. Presently, all have a severe, static, residual sensory deficit. During follow-up of five years, no evidence of neoplastic disease or immunological disorder has appeared. Because of the rapid onset, widespread and pure sensory involvement, and poor recovery, the lesion is most likely confined to the dorsal root and gasserian ganglia (sensory neuronopathy). This pattern resembles that of the experimental lesions induced by doxorubicin and pyridoxine. It appears likely that either the previously administered antibiotics or the illness for which they were administered were of pathogenetic importance. We designate this previously unrecognized disorder the acute sensory neuronopathy syndrome and suggest that it represents a distinct, readily identifiable clinical entity.
 ...
PMID:The acute sensory neuronopathy syndrome: a distinct clinical entity. 624 36

An acute episode of encephalopathy after the infusion of 16 g methotrexate is reported in a 12-year-old girl with osteogenic sarcoma. The complication occurred during the 11th treatment course, when severe vomiting and diarrhea were followed by a low urine output with consecutive toxic concentrations of methotrexate in serum and cerebrospinal fluid leading to severe systemic and central nervous system toxicity. The onset of the central nervous system toxicity was acute with slurred speech, paresis of the external rectus eye muscles, ataxia, and hemiparesis, and symptoms resolved completely after 30 hours by treatment with calcium leucovorin and forced diuresis. After management of the cerebral and systemic toxicity, high-dose methotrexate treatment could be reinstituted, and was followed by no further complications. In contrast to the transient cerebral dysfunctions, probably caused by embolization of tumor tissue in the early course of high-dose methotrexate treatment, the acute neurologic syndrome observed in the current case after the prolonged use of methotrexate seemed to be related to direct central nervous system toxicity of the drug.
 ...
PMID:Transient encephalopathy during the late course of treatment with high-dose methotrexate. 658 97

We observed a 55 y.o. right-handed woman, who was suspected of splenium tumor (glioblastoma?) by CT scan and presented bilateral crossed visuomotor ataxia proposed by Rondot et al. Left unilateral apraxia and agraphia were not found, but left unilateral hemialexia was evident by tachistoscopic examinations. In regard to bilateral crossed visuomotor ataxia, we suggested that at least there might be three possible hypotheses about its realization mechanism. (1) Callosal lesion might disconnect heterotopical fibers which runs from one occipital lobe to another frontal lobe. (2) Integrated information of visual and proprioceptive inputs in the parieto-occipital regions could not be transferred mutually to other side of the brain. (3) Functional dissociation between visual perception of "moving" and that of "position" might be the cause of this symptom. Former could be transferred via subcallosal pathway, but latter not transferred due to the callosal lesion. Hypothesis (1) could not explain, at least, "positive aspects" of this symptom, and which hypothesis is most probable might not be decided at present, because anatomical evidence and patho-plastic mechanism are not yet clarified.
 ...
PMID:[Bilateral crossed visuomotor ataxia--a case report]. 667 Oct 73

We report the clinical features, radiological studies, operative management, and follow-up data in a series of 27 patients with tentorial meningiomas. Headache and extremity or gait ataxia were the most common presenting symptoms. Signs of elevated intracranial pressure and cranial nerve, pyramidal, or cerebellar deficits were the most common findings on neurological examination. Computed tomography was the single most important diagnostic tool. Cerebral arteriography was considered important to define arterial and venous relationships to the tumor. Two patients in the series underwent cerebrospinal fluid shunting only. The others underwent an operation on the tumor, with or without a shunt. There were 2 postoperative deaths early in the series, 1 due to cerebellar swelling and the other due to brain stem infarction. With an average follow-up of 5.5 years, 19 patients are independent and have resumed their premorbid level of activity. The pathological anatomy of these lesions is described. The different operative approaches to this tumor are discussed.
 ...
PMID:Tentorial meningiomas: surgical management and results. 670 50

Thirteen patients with schwannomas of the jugular foramen were operated on at the Cleveland Clinic between 1974 and 1983. The authors' experience in managing these rare tumors is presented. Three major growth patterns of jugular foramen schwannoma were seen, and it is postulated that the position of the tumor depends on its point of origin from the nerves as they pass through the pars nervosa of the jugular foramen. The more distal lesions will expand inferiorly out of the base of the skull, and the more proximal lesions will enlarge into the posterior fossa. Tumors in the mid region will tend to expand primarily into bone. The schwannoma was primarily intracranial in six patients. In five patients the tumor expanded the bone at the base of the skull, with only a small intracranial component, and in two patients the tumor was primarily extracranial, with a small extension into the bone or posterior fossa. The presentation of the patients varied according to the tumor growth pattern. Deafness, vertigo, and ataxia were present in all patients with a major intracranial component, and in most of these there were only minimal deficits of the jugular foramen nerves. By contrast, lower cranial nerve involvement, including hoarseness and weakness of the trapezius and sternocleidomastoid muscles, occurred in patients in whom the tumor was primarily, within the bone or extracranial. Three of the five patients with the major component of the schwannoma within the bone also had deafness. Symptomatic history was longest in those with tumor mainly involving the bone at the base of the skull, and shortest in patients with entirely extracranial tumor. Surgical resection was accomplished with a joint neurosurgical-otological approach, usually combining a posterior fossa exploration with either a translabyrinthine transcochlear or infralabyrinthine procedure. The exact nature of the operation depended upon the presence of intracranial tumor and on the extent of bone or extracranial involvement. Total excision was performed in all cases. There was no operative mortality, and surgery resulted in loss of function of the ninth, 10th, and 11th cranial nerves in most patients. The major postoperative morbidity consisted of swallowing difficulties and sputum aspiration.
 ...
PMID:Jugular foramen schwannomas. 671 39

FD-1, 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil, is an anticancer agent newly developed in Japan and is a kind of marked compound of 5-fluorouracil. FD-1 changes to 3-FT and tegafur and is then converted to 5-fluorouracil. From our clinical observations, FD-1 showed excellent clinical effects in a daily dose of 600 mg. However, in some instances toxicities of central nervous system were developed. On the other hand, there is evidence that uracil enhances antitumor activity of FD-1 in the treatment of sarcoma 180 bearing mice and AH130 bearing rats. On oral administration of FD-1 plus uracil in various combination ratios, the high T/B value (ratio of the concentration of 5-fluorouracil in the tumor and blood) is obtained at a ratio of uracil to tegafur of 20 to 50. Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1. However, no tumor regression was observed in any of our cases. On the contrary, toxic manifestations were experienced in five of fifteen cases. They mainly consisted of mild G.I. toxicities. Furthermore, in one case, ataxia developed. Our clinical studies revealed no usefulness of UFD-1 in the treatment of advanced adenocarcinoma cases.
 ...
PMID:[Clinical experiences with UFD-1]. 682 Sep 5


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>